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Transforming growth factorbeta-induced (TGFBI/bIG-H3), alsoknownasbig-H3, isaprotein induciblebyTGFb1
and secreted by many cell types. It binds to collagen, forms part of the extracellular matrix and interacts with
integrins on the cell surface. Recombinant TGFBI and transgenic TGFBI overexpression can promote both
islet survival and function. In this study, we generated TGFBI KO mice and further assessed TGFBI function
and signaling pathways in islets. Islets from KO mice were of normal size and quantity, and these animals
were normoglycemic. However, KO islet survival and function was compromised in vitro. In vivo, KO donor
islets became inferior to wild-type donor islets in achieving normoglycemia when transplanted into KO diabetic
recipients. TGFBI KO mice were more prone to straptozotocin-induced diabetes than the wild-type counterpart.
Phosphoprotein array analysis established that AKT1S1, a molecule linking the AKT and mTORC1 signaling
pathways, was modulated by TGFBI in islets. Phosphorylation of four molecules in the AKT and mTORC1 signal-
ing pathway, i.e. AKT, AKT1S1, RPS6 and EIF4EBP1, was upregulated in islets upon TGFBI stimulation.
Suppression of AKT activity by a chemical inhibitor, or knockdown of AKT1S1, RPS6 and EIF4EBP1 expression
by small interfering RNA, modulated islet survival, proving the relevance of these molecules in TGFBI-triggered
signaling. Human genetic studies revealed that in the TGFBI gene and its vicinity, three single-nucleotide poly-
morphisms weresignificantlyassociatedwith type 1diabetes risks, and one with type 2diabetes risks.Ourstudy
suggests that TGFBI is a potential risk gene for human diabetes.
INTRODUCTION
Transforming growth factor beta-induced (TGFBI), also known
as big-H3, is a gene cloned from TGFb-stimulated A549 lung
adenocarcinoma cells (1). TGFBI protein has an N-terminal se-
cretory signal (amino acids 1–23), four FAS1 homologous
internal domains, and a cell attachment RGD domain at its
C terminus (2). A secreted protein, TGFBI, is also found in the
cell cytoplasm and nucleus (3). It is produced by several cell
types, such as smooth muscle cells, keratinocytes, fibroblasts
(3), proximal tubular epithelial epithelial cells (4), upon TGFb
or high-glucose stimulation (5). In addition, in situ hybridization
shows that TGFBI is expressed in the heart, blood vessels, intes-
tine, eyes and other tissues of mesenchymal origin (6), indicating
that the gene plays a general role in various organs during
ontogeny.
Although the biological significance of cytoplasmic and
nuclear TGFBI has not yet been elucidated, we have a basic
understanding of the function of secreted TGFBI. After secre-
tion, TGFBI binds to the extracellular matrix (ECM) through
interaction of the YH motif in its FAS1 domains with ECM col-
lagens I, II, IV and VI (7,8). Its FAS1 domains can interact with
a3b1, aVb3 and aVb5 integrins on the cell surface (4,9,10). Its
RGD domain at the C-terminal binds to integrins, although its
interacting integrins have not been pin-pointed (11,12). TGFBI
is also known to bind a1b1, a6b4 and a7b1(13,14), but the
domain(s) involved in such associations have not been identi-
fied. Thus, secreted TGFBI acts as a bi-functional molecule,
enhancing ECM and cell interactions, a lack of which culminates
in dysfunction of many cell types.
Indeed, when TGFBI is coated on solid phase, it induces
adhesion, reduces proliferation and inhibits the differentiation
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of keratinocytes (10). Solid-phase TGFBI enhances osteoblast
adhesion, suppresses their differentiation (9) and blocks corneal
epithelial cell adhesion and spreading (15). These biological
effects of TGFBI could be explained by triggering the cell
surface integrin signaling pathway with solid-phase TGFBI.
On the other hand, a soluble fragment containing the TGFBI
C-terminal RGD domain induces Chinese hamster ovary cell
apoptosis (2,11). In this condition, it is likely that the soluble
fragment interferes with normal cell–cell interactions between
integrins and fibronectin, as the RGD domain could bind to integ-
rins and dampen their association with fibronectins. This suggests
that TGFBI is not only necessary for ECM–cell interaction, but
might also regulate cell–cell contact, both of which are essential
for cellular function and survival. There is much controversy
regarding the effect of TGFBI on tumorigenesis. Enhanced as
well as reducedTGFBI expression has been found tobeassociated
with increased malignancy in clinical settings and animal models
(3,16). Opposite effects in integrin-triggering by the intact TGFBI
molecule and integrin-blocking by its fragments might be one of
the possible reasons for these seemingly controversial outcomes.
Point mutationsof theTGFBIgene inhumans lead toseveral types
of corneal dystrophy (3,17,18), although the underlying mechan-
isms are not understood.
Our earlier study demonstrated that recombinant TGFbi could
preserve the integrity and enhance the function of cultured islets
(19). Islets from TGFBI transgenic (Tg) mice with actin
promoter-driven TGFBI overexpression showed better integrity
and insulin release after in vitro culture. In vivo, b-cell prolifer-
ation was detectable in Tg but not wild-type (WT) pancreata.
At the age above 12 months, Tg pancreata contained giant islets.
Tg mice displayed better glucose tolerance than the controls.
Tg islets were more potent in lowering blood glucose when
transplanted into syngeneic mice with streptozotocin-induced
diabetes, and these transplanted islets also underwent regener-
ation. Our results indicate that TGFbi is a vital trophic factor
promoting islet survival, function and regeneration.
In the current study, we generated TGFBI gene knockout
(KO) mice. In vitro, KO islet survival and function were compro-
mised. In vivo, KO mice were more susceptible to low-dose
streptozotocin (STZ)-induced diabetes. KO donor islets were
inferior to WT donor islets in achieving normoglycemia when
transplanted into KO diabetic recipients. At the molecular level,
TGFBI activated the FAK/AKT/ATK1S1/RPS6/EIF4EBP1 sig-
naling pathway in the islets. Genetic studies in humans indicate
that TGFBI was a risk factor for both type 1 and type 2 diabetes
(T1D and T2D).
RESULTS
Generation and general features of TGFBI KO mice
To definitively understand TGFBI’s function in islet biology, we
generated TGFBI KO mice. The targeting strategy is illustrated
in Figure 1A. We deleted exon 4–11 of the TGFBI gene, hence
the deletion of amino acid sequence from 101 to 559 of the 683
amino acid TGFBI protein. All the functional domains of the
protein were eliminated. Germ-line transmission of the targeted
Tgfbi allele was confirmed by Southern blotting of tail DNA
(Fig. 1B). The targeted and WT alleles had an 8.8-kb and a
12.7-kb BglII/BglII band, respectively, using the 5′ probe; and
a 7.0-kb and a 5.3-kb NcoI/NcoI band, using the 3′ probe.
KO mice were backcrossed to the C57BL/6 background
for two generations when islet transplantation experiments
were carried out. For the rest of the experiments, KO and WT
mice in the C57BL/6 background (backcrossed to C57BL/6 for
8–10 generations) were studied.
TGFBI deletion in KO mice at the mRNA level in the kidneys
and islets was verified by reverse transcription–quantitative
polymerase reaction (RT–qPCR), as illustrated in Figure 1C
and D, respectively. Deletion of KO mice TGFBI protein was
demonstrated by serum TGFBI levels (Fig. 1D). TGFBI concen-
tration in the sera of heterozygous mice was 50% that of WT
mice, while it was not detectable in KO mice. The TGFBI KO
mice were fertile and had no visible anomalies. Although a pre-
vious report showed that TGFBI KO mice have reduced body
size which is caused by smaller bones (20), we did not notice
obvious differences in body sizes between our KO and WT mice.
TGFBI KO islet survival and function are compromised
in vitro
Our previous study showed that islets can produce TGFBI by
themselves, and TGFBI can promote islet survival and function
(13,14,19). We questioned whether, conversely, TGFBI deletion
in islets was detrimental to their survival and function. WT and
KO islets were cultured in serum-free medium for 24 h, and
their morphology, apoptosis and insulin release were then
assessed. As seen in Figure 2A, KO islets quickly lost their
integrity after 24-h culture in serum-free medium, unlike WT
islets. Quantitative assessment of islet integrity is illustrated in
Figure 2B. Fewer than 5% of WT islets disintegrated after 24 h,
compared with .25% of KO islets. At this time point, much
higher percentages of KO islet cells than WT cells underwent
apoptosis (53 versus 38%; Fig. 2C). KO islets presented a signifi-
cantly lower ratio of high glucose- versus low glucose-stimulated
insulin release than WT islets (Fig. 2D), corroborating the apop-
tosis results, and strongly suggesting that apoptotic islet cells
were b-cells.
TGFBI KO islets function is compromised in vivo
We conducted a series of in vivo experiments to assess KO islet
function. Islets in KO pancreata were of similar size and number
as those in WT pancreata according to histology (Supplementary
Material, Fig. S1A) and islet count after isolation (Supplemen-
tary Material, Fig. S1B), blood glucose was normal in KO
mice (Supplementary Material, Fig. S1C). Their glucose toler-
ance was similar to that of WT mice (Supplementary Material,
Fig. S1D). These data indicate that a lack of TGFBI does not
affect islet development and function under normal circum-
stances in vivo.
However, the necessity of TGFBI for islet function was
revealed when islets were stressed. We transplanted KO islets
into diabetic KO and WT recipients. Transplanted KO islets
were significantly less potent in reversing the diabetic condition
of KO recipients than that of WT recipients. The former group
presented higher glucose levels (Fig. 3A, upper panel) and a
lower percentage of recipients returning to normoglycemia
(Fig. 3A, lower panel). Interestingly, such a detrimental effect
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Figure 1. Generation of TGFBI KO mice. (A) Targeting strategy generating TGFBI KO mice. The light gray vertical bars are exons. The hatched squares on 5′ and
3′ sides of the mouse TGFBI WT genome represent the sequences serving as probes for genotyping by Southern blotting. The sizes of WT and mutated alleles cut by
BglII and NcoI are indicated. (B) Genotyping of TGFBI mutant mice. Tail DNA was digested with BglII or NcoI, and analyzed by Southern blotting, with the 5′ and 3′
probes, respectively. The locations of the probes are indicated in (A). A 7.0-kb band representing the WT allele and a 5.3-kb band representing the recombinant allele
are indicated by arrows. (C and D) Absence of mRNA expression in TGFBI KO tissues. mRNA levels from WT and KO kidneys (C) and islets (D) were analyzed by
RT–qPCR for TGFBI mRNA expression. The results are expressed as ratios of TGFBI versusb-actin signals with means+SD from three pairs of KO and WT mice.
(E) Absence of TGFBI protein in sera of Tgfbi KO mice. Sera from WT, heterozygous and KO mice were assayed by TGFBI ELISA. Samples were assessed in du-
plicate by ELISA and mouse numbers were indicated. Means+SD for each group are reported.
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due to a lack of TGFBI was obvious only when KO islets were
transplanted to KO recipients. When KO islets were transplanted
to diabetic WT recipients, they were no worse than WT islets in
terms of lowering blood glucose (Fig. 3B, upper panel) and ren-
dering the recipients euglycemic (Fig. 3B, lower panel). The lack
of TGFBI alone in the recipients was not sufficient to reveal the
effect of this protein on islet protection, because WT islets func-
tioned well in diabetic KO recipients as they did in diabetic WT
recipients, again in terms of lowering blood glucose (Fig. 3C,
upper panel) and rendering the recipients euglycemic (Fig. 3C,
lower panel).
Collectively, these data indicate that TGFBI in the WT milieu
surrounding transplanted KO islets is sufficient for donor KO
islets to function normally, and TGFBI produced by WT islets
is also sufficient for them to function normally in the recipient
KO milieu. The detrimental effect of TGFBI deletion is revealed
only when islets are deprived of TGFBI produced both by them-
selves and the milieu around them under stress conditions, such
as islet transplantation.
In an additional experiment, we assess the consequence of a
lack of TGFBI in both the islets and their environment under a
simulated T1D condition, i.e. multiple low-dose STZ-induced
diabetes. Such manipulation causes an chronic inflammatory
condition in the pancreata (10,21,22). The KO and WT mice
were treated with suboptimal multiple low doses of STZ. This
caused a slow increase of blood glucose over a period of
20–25 days in WT mice, although we titrated the STZ dose so
that most of the WT mice did not reach the 12 mmol/l threshold
of diabetes (Fig. 3D). However, there was significantly higher
blood glucose levels and diabetes incidence in the KO mice.
This suggests that individuals with TGFBI loss-of-function
mutations might have increased T1D risks.
TGFb1 stimulates TGFBI secretion by islets
and by tissues surrounding transplanted islets
TGFBI was first identified as a molecule produced by
TGFb1-stimulated lung carcinoma cells (1,9). TGFb1 production
Figure 2. TGFBI KO islet survival and function is compromised in vitro. (A and B) TGFBI KO islets quickly lose their integrity in culture. Freshly isolated WT and
TGFBI KO islets were cultured in F-12K serum-free medium containing 2% BSA and 1X MEM non-essential amino acids for 24 h. Their morphology is illustrated in
micrographs (A). About 150–200 islets from each mouse were assessed visually, and the percentages of those that lost integrity (defined as having lost 50% of capsule
surrounding the islets) were registered. Means+SD of the percentage of each group (based on three independent experiments) are illustrated (B), and statistical sig-
nificance of the difference is indicated (P ¼ 0.006; Student’s t test). (C) TGFBI KO islets are prone to apoptosis in culture. WT and KO islets were cultured in serum-
free medium for 24 h, as described above, dispersed and stained with annexin V, followed by flow cytometry analysis. Percentages of annexin V-positive cells are
indicated. The experiment was performed 3 times, and histograms of a representative experiment are shown, in which the WT and KO islet cells showed 37.9%
and 53% apoptosis, respectively. (D) TGFBI KO islet function is compromised after culture. WT and KO islets were cultured in serum-free medium for 24 h. Ten
islets were picked and stimulated sequentially with low- and high-glucose concentrations (2.8 and 16.7 mM, respectively). Insulin released into medium after stimu-
lation was assessed by ELISA in duplicate samples. Ratios of released insulin upon low- and high-glucose stimulation were calculated. Means+SD of the ratios of
each group (from three independent experiments) are reported, and statistically significant differences are indicated (P ¼ 0.026; Student’s t test).
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is upregulated at trauma sites as part of wound-healing processes
(15,23). It is logical to expect that isolated islets, which have
experienced mechanical and enzymatic insults, will upregulate
TGFb1 secretion. We have demonstrated that this was indeed
the case: isolated WT islets produced significantly high TGFb1
levels within 48 h of isolation in the serum-free culture condition
(Fig. 4A). We further showed that under the serum-free condition,
employed to exclude the possible influence of TGFb1 from bovine
serum, TGFBI secretion was upregulated by WT islets within 48 h
after isolation, and such secretion could be drastically boosted by a
near-physiological concentration of exogenous TGFb1 (20 ng/nl)
within another 48-h culture (Fig. 4B). Taken together, it proved
that TGFb1 could upregulate TGFBI secretion by islets and
that upregulated TGFBI secretion shortly after islet isolation
is, at least in part, caused by endogenously upregulated TGFb1
stimulation.
We wondered whether WT tissues surrounding transplanted
islets, in this case the renal parenchyma, could also produce
TGFBI. Due to technical difficulties, mainly the interference
of high serum TGFBI levels, it is not feasible to accurately
measure the TGFb1 and TGFBI proteins in tissue fluid exodus
under the renal capsule where the islets were transplanted. We
quantified the mRNA levels of these two molecules in tissues
(i.e. renal parenchyma) adjacent to where the islets were
implanted. As shown in Figure 4C, renal parenchyma near the
capsule of sham-operated kidneys had significantly upregulated
TGFb1 mRNA levels 24 h after the operation, compared with
unmanipulated kidneys. They were accompanied by upregulated
TGFBI mRNA levels in this tissue (Fig. 4D).
Phospho-protein array analysis of TGFBI-triggered
signaling pathways
TGFBI is known to bind integrins. In our previous study, we
demonstrated that FAK, which is positioned upstream in the in-
tegrin signaling pathway, is activated in islets upon TGFBI
stimulation (19). We interrogated the Full Moon BioSystem
phospho-protein array, which contains Abs against 402 phos-
phorylated kinases, adaptor proteins, and transcription factors as
well as Abs against the total proteins of these molecules,
looking for additional molecules involved in the TGFBI signaling
pathway. Islets from transgenic mice with actin-promoter-driven
TGFBI overexpression were used as starting material as they
receive excessive TGFBI stimulation; islets from WT mice
were used as controls. Ratios of phospho-protein signals versus
total protein signals were first determined, and fold changes of
Tg versus WT islet ratios were calculated. Molecules with fold
changes .1.5 or ,0.67 are listed in Table 1. Considering the
relevance of these molecules to islet function based on the existing
literature, we selected six molecules, i.e. DAXX, p27Kip1,
AKT1S1, MAPKAPK2, SMAD1 and calmodulin, for validation
by western blotting. Only AKT1S1 and p27Kip1 phosphorylation
Figure 3. KO islet function is compromised after transplantation into KO diabetic recipients. Numbers of mice (n) per group are indicated. Blood glucose levels are
shown in the upper row and % of mice with normoglycemia is shown at the bottom row. Data from different groups were assessed by ANOVA. For percentages of
normoglycemic mice in different groups, ANOVA was performed after they were square-rooted, followed by arcsin transformation. P values are reported. (A) KO
islets perform poorly after transplantation into KO recipients. A dose-limiting number of KO islets (350 islets/recipient) were transplanted under the renal capsules of
syngeneic WT and KO recipients, which were rendered diabetic by prior STZ treatment. Blood glucose levels of the recipients were monitored for 31 days. Blood
glucose levels of the different groups and the percentages of mice that reached normoglycemia (,12 mM) are reported. (B) KO and WT donor islets have comparable
function in WT recipients. Islets from KO and WT donors were transplanted into WT diabetic recipients; their blood glucose levels and percentages of mice becoming
normoglycemic were monitored for 31 days, as described in (A). (C) WT donor islets have comparable function in WT and KO recipients. Islets from WT donors were
transplanted into diabetic WT and KO recipients; their blood glucose levels and percentages of mice becoming normoglycemic were monitored for 31 days, as
described in A. (D) KO mice are prone to multiple low-dose STZ-induced diabetes. KO and WT male mice were treated i.p. with low dose STZ (40 mg/kg, q.d.
for 5 days). Their blood glucose levels and percentages of mice with normoglycemic were monitored once every 3 days from Day 6 until Day 34.
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showed discernible and reproducible differences between Tg and
WT islets (Fig. 5 and data not shown). The former was further
investigated in the following section.
TGFBI activates the FAK/AKT/AKT1S1/mTOR pathway
We reported previously that TGFBI retains higher FAK activity
in islets after their isolation, and FAK knockdown compromises
islet function (19), establishing an upstream event in the
TGFBI signaling pathway. We elected to further study the role
of AKT1S1 in TGFBI signaling, because it is a substrate of
AKT which is downstream of FAK, and it is also part of the
mTOR signaling pathway which is critical in cell survival and
proliferation (24). As seen in Figure 5, we confirmed that
AKT1S1 phosphorylation in islets was increased within 4 h of
TGFBI stimulation. Such upregulation is accompanied by
higher AKT phosphorylation, reflecting enhanced AKT activity
which is responsible for AKT1S1 phosphorylation. AKT1S1
phosphorylation allows it to dissociate from mTOR complex
1 (mTORC1) and renders mTOR active (24). Indeed, we demon-
strated that two downstream molecules of mTOR, i.e. RPS6 and
EIF4EBP1, underwent increased phosphorylation in TGFBI-
treated islets, indicating mTOR signaling pathway activation.
Taken together, these data suggest that TGFBI could trigger sig-
naling along the FAK/AKT/AKT1S1/mTOR pathway.
It needs to be mentioned that within 4 h of islet isolation,
AKT1S1 and RPS6 phosphorylation was increased, as was, to
a small extent, AKT phosphorylation, even in the absence of
exogenous TGFBI (Fig. 5, second column). It is likely that the
islet isolation process and/or the new culture environment
were capable of activating these molecules through so-far
unknown mechanisms. Also, TGFBI secreted by islets them-
selves during this period could act as paracrine to stimulate
the islets. Nevertheless, the exogenous TGFBI could further
enhance the augmented phosphorylation of these molecules
(Fig. 5, third column).
To prove that FAK/AKT/AKT1S1/mTOR pathway activa-
tion was relevant to the observed role of TGFBI in islet survival,
we used kinase inhibitors and small interfering RNA (siRNA)
knockdown in islets to assess whether these molecules could
blunt TGFBI’s beneficial effect on islets. We have already
demonstrated that FAK knockdown by siRNA compromises
islet function (19), proving its importance in islet function.
The next molecule in the pathway, AKT, underwent augmented
phosphorylation in islets upon TGFBI stimulation. The rele-
vance of AKT function to islet survival was ascertained with
Figure 4. TGFb1 and TGFBI production by islets and renal parenchyma. (A) TGFb1 production by isolated islets. WT islets were cultured in F-12K serum-free
medium (200 islets/0.2 ml/well in 48-well plates) for the durations indicated. TGFb1 in supernatants was measured by ELISA of duplicate samples. Means+SD
of TGFb1 levels are reported. (B) TGFBI production by WT islets upon exogenous TGFb1 stimulation. WT islets were cultured as described in (A), and TGFBI
in supernatants was measured at different time points by ELISA of duplicate samples. In some culture, recombinant mouse TGFb1 (20 ng/ml) was added at 48 h
after the initiation of culture. Means+SD of TGFBI levels are reported. In (A and B), experiments were performed more than twice, and data from representative
experiments are reported. (C and D) TGFb1 and TGFBI production by renal parenchyma after trauma. The left kidneys of WT mice were sham-operated to mimic islet
transplantation procedures, After 48 h, the renal parenchyma near the woundwas pared, and its RNA extracted to measure TGFb1 (C) and TGFBI (D) mRNA levels by
RT–qPCR in duplicate. The results are expressed as ratios of TGFb1 or TGFBI versusb-actin signals. Unmanipulated right kidneys served as controls, and lines link
the ratios of two kidneys (operated versus unmanipulated) from the same mouse. P values (paired Student’s t test) are reported.
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an inhibitor (AKT inhibitor IV). Islets were cultured in serum-
free medium to avoid possible influence of exogenous TGFBI
from bovine serum. In the absence of TGFBI, AKT inhibitor
IV at 1 mM had no significant effect on islet cell survival
(Fig. 6A: left column of histograms and empty bars of right
panel), indicating that the inhibitor, by itself at this concentra-
tion, did not constitutively impact islet survival. TGFBI signifi-
cantly improved islet survival (Fig. 6A: top row of histograms
and left group in bar graph on the right), but the AKT inhibitor
revoked its beneficial effect, and islet cell apoptosis returned
to a level similar to that without TGFBI treatment (Fig. 6A:
lower row of histograms and left group in bars of the bar
graph), suggesting that AKT is in the TGFBI signaling
pathway with regard to TFGBI’s function in islet survival.
AKT1S1 (PRAS40) is a known substrate of AKT. It likely
connects the AKT signaling pathway to the mTOR pathway.
AKT1S1 binds mTORC1 via Raptor and can inhibit mTORC1
autophosphorylation as well as its kinase activity (25).
AKT1S1 phosphorylation at Thr246 by AKT leads to its dissoci-
ation from mTORC1 (26), and releases its inhibitory effect on
mTORC1 (27). We demonstrated that TGFBI-induced AKT1S1
phosphorylation at Thr246 (Fig. 5). Reduced unphosphorylated
AKT1S1 levels in cells, in theory, would equate with AKT1S1
dephosphorylation, and release the mTORC1 inhibition. Would
such a decrease of unphosphorylated AKT1S1 be beneficial to
islets? We conducted siRNA knockdown of AKT1S1 to answer
this question. AKT1S1 knockdown at the mRNA level was
ascertained by RT–qPCR (Fig. 6B: upper left panel). WT islets
cultured in serum-free medium for 48 h resulted in a high rate
of apoptosis, but AKT1S1 knockdown significantly reduced
such apoptosis, suggesting that the TGFBI-induced decline of
unphosphorylated AKT1S1 level would exert a similar protective
influence on islet apoptosis.
mTORC1 has two kinase substrates: EIF4EBP1 and p70S6K,
whose phosphorylation and activation will lead to RPS6 phos-
phorylation. EIF4EBP1 is a repressor of protein translation
(28). It has seven identified phosphorylation sites, i.e. Thr37,
Table 1. Phospho-protein array analysis of TGFBI Tg versus WT islets




TGFB1 Tg WT Tg/WT
BRCA1 (Phospho-Ser1457) 0.97 0.54 1.80
DAXX (Phospho-Ser668) 0.08 0.05 1.76
VASP (Phospho-Ser157) 0.47 0.27 1.75
p27Kip1 (Phospho-Ser10) 1.66 1.02 1.62
Histone H3.1 (Phospho-Ser10) 1.03 0.65 1.58
MEF2A (Phospho-Ser408) 2.27 1.48 1.54
AKT1S1 (Phospho-Thr246) 0.26 0.18 1.49
Paxillin (Phospho-Tyr31) 1.41 0.95 1.49
BLNK (Phospho-Tyr96) 0.22 0.35 0.63
Cyclin B1 (Phospho-Ser147) 0.49 0.85 0.58
MAPKAPK2 (Phospho-Thr334) 0.05 0.11 0.41
Smad1 (Phospho-Ser465) 0.31 1.08 0.28
Calmodulin (Phospho-Thr79/Ser81) 0.14 0.74 0.18
Islets from Tg and WT mice were isolated, and cultured for 4 h in F-12K
serum-free medium. Islet lysates were analyzed by Full Moon BioSystem
(Sunnyvale, CA, USA) phospho-protein array. Samples were run in triplicate.
The names of proteins and their phosphorylation sites assessed are indicated in
column 1. The ratios of mean signals of phospho-protein versus total protein (P/T
ratio) are listed in columns 2 (Tg islets) and 3 (WT islets). Fold differences
between the Tg ratio over the WT ratio of each protein (P/T ratio changes) were
calculated and listed in the last column. Only proteins with fold differences
between Tg and WT islets above 1.5 or less than 0.67 are included in the table.
Figure 5. Phosphorylation of molecules putatively involved in TGFBI signaling according to immunoblotting. WT islets were either lysed directly or cultured for
4 h in presence of TGFBI (5 mg/ml) in F-12K serum-free medium and then lysed, as indicated. Lysates were analyzed for phospho-AKT (P-AKT; Ser473),
total AKT (T-AKT), phospho-AKT1S1 (P-AKT1S1; Thr246), total AKT1S1 (T-AKT1S1), phospho-RPS6 (P-RPS6; Ser235/236), total RPS6 (T-S6),
phospho-EIF4EBP1(P-EIF4EBP1; Thr37/46), and total EIF4EBP1 (T-EIF4EBP1). Beta-actin was included as an additional loading control. The experiments
were conducted three times in total, and data from a representative experiment are reported. All blotting in (A) were derived from 1 SDS–PAGE run and one mem-
brane. The data from all three experiments were analyzed by densitometry, and the ratios of signal strength of phosphoproteins versus that of total proteins were illu-
strated in bar graphs in (B). The differences between TGFBI-treated verses the controls are significant (∗P , 0.05, paired Student’s t test).
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Figure 6. Islet survival upon modulation of AKT, AKT1S1, RPS6 and EIF4EBP1 activity and expression. Three independent experiments were conducted in (A),
(B) and (C), and histograms of a representative experiment are presented, with percentages of annexin V-positive cells. (A) AKT inhibitor IV revokes the beneficial
effect of TGFBI on islet survival. WT islets were cultured in F-12K serum-free medium for 72 h in presence and absence of human recombinant TGFBI (5 mg/ml) and
AKT inhibitor IV (1 mM), as indicated. Islet cell apoptosis was measured according to annexin V staining, followed by flow cytometry. (B) AKT1S1 and EIF4EBP1
siRNA transfection reduces islet apoptosis. WT islets were transfected with siRNAs targeting AKT1S1 or EIF4EBP1, or with control siRNA. They were cultured in
F-12K serum-free medium for 72 h. AKT1S1 and EIF4EBP1 mRNA knockdownwas confirmed by RT–qPCR (upper row), with expression as ratios (means+SD) of
targeting gene signals versus b-actin signals. Islet cell apoptosis was measured by annexin V staining, followed by flow cytometry. (C) RPS6 siRNA transfection
revokes the beneficial effect of TGFBI on islet survival. WT islets were transfected with siRNAs targeting RPS6, or with control siRNA. They were cultured in
F-12K serum-free medium for 72 h in absence or presence of TGFBI (5 mg/ml), as indicated. Rps6 mRNA knockdown was confirmed by RT–qPCR (upper row),
with expression as ratios (means+SD) of targeting gene signals versus b-actin signals. Islet cell apoptosis was measured by annexin V staining, followed
by flow cytometry. The experiments in (A), (B), and (C) were conducted a total of three times, and the data are summarized in bar graphs at the right of each
panel. Differences with statistical significance (paired Student’s t tests) are indicated with asterisks (∗P , 0.05; ∗∗P , 0.01).
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Thr46, Ser65, Thr70, Ser83, Ser101 and Ser112, phosphoryl-
ation of the first two being a priming event (29,30). Hypopho-
sphorylated EIF4EBP1 interacts with EIF4E and prevents
recruitment of the translation machinery to mRNA, inhibiting
translation. EIFE4BP1 phosphorylation results in the disassoci-
ation of this protein with EIF4E, releasing its translation inhibi-
tory effect, which has a broad, positive influence on cell biology,
such as proliferation, survival and function. While TGFBI KO
islets were prone to apoptosis (Fig. 2), WT islets upon TGFBI
stimulation presented improved survival (19), accompanied by
upregulated EIF4EBP1 phosphorylation (Fig. 6). Such phos-
phorylation should reduce the amount of hypophosphorylated
EIF4EBP1 in a given cell and result in release of the inhibitory
effect of EIFEBP1 on translation. Is this a relevant event for
better islet survival? We undertook siRNA knockdown of
EIF4EBP1 in islets. mRNA knockdown was confirmed by
RT–qPCR (Fig. 6B: left panel of first row). Islets transfected
with Eif4ebp1 siRNA showed significantly reduced apoptosis
(Fig. 6B: histograms in second row and bar graph on the right),
indicating a beneficial effect of reduced total EIF4EBP1 levels
including unphosphorylated one, similar to that caused by
EIF4EBP1 phosphorylation.
The other mTORC1 downstream signaling molecule RPS6 is
a component of the ribosome complex machinery for protein
synthesis. It has been proposed that ribosomes with the highest
proportion of phosphorylated RPS6 become active to serve as
part of polysomes (31). RPS6 phosphorylation sites have been
mapped to Ser235, Ser236, Ser240, Ser244 and Ser247.
Knock-in mice with these residues mutated to alanines suffer
from small pancreatic b-cells, diminished levels of pancreatic
insulin, hypoinsulinemia and impaired glucose tolerance (32),
revealing essential roles of RPS6 phosphorylation in islet
biology. We demonstrated that TGFBI stimulation upregulated
RPS6 phosphorylation (Fig. 5). To answer the question whether
such upregulation is relevant to the observed beneficial effect of
TGFBI on islet survival, we transfected WT islets with RPS6
siRNA. RPS6 mRNA knockdown was confirmed by RT–qPCR
(Fig. 6C: upper left panel). TGFBI increased islet survival
(Fig. 6C: upper right panel of histograms and bar graph on the
left). WT islets with RPS6 knockdown by siRNA manifested no
significant difference in apoptosis from control siRNA-
transfected islets (Fig. 6C: left column of histograms and empty
bars of the bar graph on the right), indicating that at this level of
knockdown, the survival of islets was not directly affected.
However, such RPS6 knockdown revoked the beneficial effect
of TGFBI on islet survival (Fig. 6C: right column of histograms
and solid bars in the bar graph on the left), indicating that RPS6
protein levels and, consequently, phosphorylated RPS6 protein
levels are critical for TGFBI’s role in islet survival.
TGFBI as a diabetes-risk gene in T1D and T2D patients
Single-nucleotide polymorphisms (SNPs) that were observed to
be significantly associated with diabetes phenotypes are pre-
sented in Table 2. The locations of the observed significant
SNPs within the queried region are shown in Figure 7A and B.
Three SNPs, rs139897010, rs181018777 andrs76629798,were
found to be associated with T1D in the Wellcome Trust Case
Control Consortium (WTCCC) genome-wide association study
(GWAS) dataset (33) at P-values of 0.0000193, 0.0000209 and
0.00010619, respectively, well below the Bonferroni-corrected
P-value at 0.00119 (dotted line in Fig. 7A). The odds ratios for
these three SNPs were 2.45, 2.44 and 1.98, respectively.
rs139897010 is located 24.064 kb 3′ of TGFBI; rs181018777 is
located 32.802 kb 3′ of TGFBI and appears to be in high linkage
disequilibrium (LD) with rs139897010; rs76629798 is intronic
within TGFBI. SNPs rs139897010 and rs181018777 are rare var-
iants recently discovered in the 1000 genomes sequencing project
(http://www.1000genomes.org) (34).
Fasting glucose levels in nondiabetic adults can reveal
pre-T2D conditions and impaired glucose tolerance. GWAS
have been conducted for the association of SNPs with fasting
glucose levels with a view to identify T2D-risk genes, and
indeed some of these are identical to known T2D-risk genes
(35,36). One SNP, rs916950, was associated with both fasting
glucose and body mass index (BMI)-adjusted fasting glucose
among nondiabetics in the Meta-Analysis of Glucose- and
Insulin-related traits Consortium (MAGIC) meta-analysis data
(22) at P-values 3.104 × 1024 and 7.926 × 1024, respectively.
If we correct for one phenotype test, this SNP is significant
(dotted line in Fig. 7B represents the corrected P-value using
one phenotype test) for both fasting glucose and BMI-adjusted
fasting glucose. If we correct for two phenotype tests which is
highly conservative for these correlated phenotypes, rs916950
is significant only for fasting glucose. rs916950 is located
25.985 kb 5′ of TGFBI gene.
The locations of the SNPs in relation to the known H3K4Me1
marks (mono-methylation of lysine 4 of the H3 histone protein)
Table 2. TGFBI SNPs significantly associated with T1D and T2D phenotypes
rs Number Phenotype/study Position (Build 36) Position (Build 37) P-value MAF Description
rs76629798 T1D/WTCCC 135 423 309 135 395 410 0.00010619 0.0666 Intronic
rs139897010 T1D/WTCCC 135 451 470 135 423 571 0.0000195 0.0014 24.064 kb 3′ of TGFBI
rs181018777 T1D/WTCCC 135 460 208 135 432 309 0.0000209 0.0014 32.802 kb 3′ of TGFBI in very
high LD with rs139897010
rs916950 Fasting Glucose/MAGIC 135 366 498 135 338 599 0.0003104 0.2621 25.985 kb 5′ of TGFBI
rs916950 Fasting Glucose Adjusted
by BMI/MAGIC
135 366 498 135 338 599 0.0007926 0.2621 25.985 kb 5′ of TGFBI
Five SNPs located within a region from 50 kb upstream to 50 kb downstream of the TGFBI gene showed significant association with T1D or fasting blood glucose
(a T2D-related phenotype). There are 42 independent LD blocks within this region, and the calculated Bonferroni-corrected P-value is 0.00119 (0.05/42 ¼ 0.00119).
MAF of these SNPs is indicated.
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H3K4Me2 marks (tri-methylation of lysine 4 of the H3 histone
protein), DNase I hypersensitive clusters and transcription
factor-binding sites in the TGFBI gene and its 5′ and 3′ adjacent
regions are shown in Supplementary Material, Figure S2.
rs76629798, rs139897010, and to a lesser extent, rs916950, are
in the H3K4Me1 mark-rich, DNase I-sensitive clusters and tran-
scription factor-binding regions, according to the University of
California Santa Cruz Genome Browser (http://genome.ucsc.
edu/) (37).
DISCUSSION
In this study, we employed genetically manipulated mice and
analyzed human GWAS datasets to determine the role of
TGFBI in diabetes pathogenesis.
We compared islet integrity, survival and function of KO and
WT islets in vitro. All these parameters were compromised in
KO islets, but such compromise was evident only when they
were cultured in serum-free medium. A very likely reason is
that fetal calf serum (FCS) contains bovine TGFBI, which
might be cross-reactive to murine TGFBI. It is conceivable
that exogenous bovine TGFBI in serum could minimize the dif-
ference between KO and WT islets with regard to TGFBI avail-
ability, and make KO islets as healthy and functional as WT
islets. KO islets became inferior to WT islets only in serum-free
medium, because no exogenous or endogenous TGFBI was
available. Of course, islets cultured in serum-free medium
were not as healthy as those in medium with 10% FCS, and up
to 40–50% of the islets became apoptotic in 2 days (Figs 2
and 7), compared with 10% of those cultured in medium
with 10% FCS (19). On the other hand, such a high rate of apop-
tosis was a suitable condition to test the survival-promoting
effect of TGFBI.
TGFBI generated by isolated islets seems to be part of a self-
protecting mechanism for them to cope with the damage they ex-
perience. TGFBI production is known to be stimulated by TGFb1
(1). We demonstrated that islets which experienced trauma during
isolation significantly upregulated their TGFb1 production
(10-fold) within 48 h (Fig. 5A). Subsequent TGFBI production
by isolated islets in vitro could be a consequence of the initial
TGFb1 upregulation, although we cannot exclude the possibility
that there are TGFb1-independent TGFBI upregulation mechan-
isms in islets.Previously,wereported that isletsafter isolationpre-
sented 4–5-fold upregulation of TGFBI mRNA (19) within 16 h.
Despite the increase of TGFb1 and TGFBI mRNA upregulation,
we observed only a moderate increment of TGFBI protein levels
after 48-hculture.Possibleexplanationsofsuchdiscrepanciesare:
(i) in our current experiments, we employed serum-free medium
that was not optimal for cellular function, including TGFBI
protein synthesis, unlike our previous experiments on medium
with 10% FCS; (ii) TGFb1 secretion was too diluted by the
culture medium (only about 100 pg/ml) to drastically stimulate
islet TGFBI production. When 20 ng/ml TGFb1, which was
still within the range of physiological andpathophysiological con-
centrations (10–20 ng/ml, as seen in normal and diabetic patients
(38), was added to culture, a significant, additional 4-fold increase
of TGFBI secretion was achievedwithin another 48 h (Fig.4B). In
islet transplantation, it is conceivable that the local TGFb1 pro-
duced by islets and accumulated in their vicinity could well
reach physiological and pathophysiological concentrations.
TGFBI generated by the islets alone was not sufficient to
confer apparent in vivo benefit, as KO and WT islets transplanted
into WT recipients showed no significant difference in terms of
lowering blood glucose (Fig. 3C). KO donor islets became only
inferior when the recipients were also KO (Fig. 3A). This sug-
gests that TGFBI at transplantation sites in WT recipients is suf-
ficient to support KO donor islet function. One source of TGFBI
was serum, which contained 400 ng/ml TGFBI in WT mice
(Fig. 1E). Another source of TGFBI in vivo might be the
tissues surrounding transplanted islets in the islet transplantation
setting. In our animal model, we transplanted islets under the
renal capsule. As with islets, trauma during islet transplantation
at transplantation sites could trigger local TGFb1 release which,
in turn, could stimulate TGFBI secretion by islets or tissues
surrounding the islets. Such local TGFBI, plus that from serum
Figure 7. Association of SNPs in the TGFBI gene and its vicinity with T1D and
T2D-related phenotype in WTCCC and MAGIC GWAS studies. (A) Significant
association of 3 SNPs in the TGFBI gene and its 3′ untranslated region with T1D.
Positions and –log (P-values) of SNPs from 50 kb upstreamto 50 kb downstream
of the TGFBI gene are indicated. The dotted line represents the Bonferroni-
corrected P-value at 1.19 × 1023. The names of 3 SNPs with P-values below
the corrected P-value are indicated. (B) Significant association of a SNP in the
5′ untranslated region of the TGFBI gene with fasting glucose levels. Positions
and –log (P-values) of SNPs from 50 kb upstream to 50 kb downstream of the
TGFBI gene are indicated. The dotted line represents the Bonferroni-corrected
P-value at 1.19 × 1023 for one phenotype test. The name of SNP with P-value
below the corrected P-value without (diamond) and with BMI-adjustment
(dot) is shown.
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in WT mice, confers beneficial and protective effects on trans-
planted WT and KO islets. This explains why the detrimental
effect of missing TGFBI on KO islets was only revealed in KO
and not in WT recipients (Fig. 3), because, in the former, no
TGFBI was available from the milieu surrounding transplanted
islets. In a clinical situation, islets were transplanted into the
liver through the portal vein. In this case, trauma to the liver
tissue is limited, and, consequently, there would not be
trauma-induced TGFb1 secreted by the liver parenchyma sur-
rounding transplanted islets. However, recipient patients all
have underlying diabetes, and diabetics tend to manifest elevated
serum TGFb1 levels, especially if renal damage is involved
(39,40). The increased TGFb1 level in such patients might
trigger TGFBI secretion by various tissues, including those sur-
rounding transplanted islets and, paradoxically, provide some
protection to islets.
AKT and mTORC1 are both critical kinases, to each of which
multiple upstream signaling events converge, and of which
many downstream cellular events, such as cell proliferation, dif-
ferentiation, survival and function, are affected (41). AKT1S1, a
substrate of AKT, could be considered as a link between the two
signaling pathways involving AKT and mTORC1, respectively,
as its phosphorylation by AKT at Thr246 makes it dissociate
from mTORC1 and release its inhibition of mTORC1 activity.
We identified several signaling molecules in the TGFBI signal-
ing pathway and showed that TGFBI-triggered signals starting
from FAK were propagated to AKT, and were then linked to
the mTORC1 pathway, in which RPS6 and EIF4BP1 were phos-
phorylated. Our finding that the beneficial effect of TGFBI on
islet survival is due in part to its signaling through the
mTORC1 pathway is compatible with a previous report that
upregulation of mTORC1 activity improves b-cell function
and increases islet mass (42). We are aware that signaling path-
ways are highly connected and interactive, with each molecule in
the pathway networking with multiple substrates/associating
proteins. For example, AKT1S1 knockdown in HeLa cells
could protect them from apoptosis, similarly to what we see in
islets, but such protection is independent of its inhibitory effect
on mTORC1 (25), suggesting that AKT1S1 interacts with
other signaling molecules in addition to mTORC1. Therefore,
we cannot rule out the possibility that AKT1S1 might affect
events in addition to the mTORC1 pathway, and such interaction
confers beneficial effects to islets upon TGFBI stimulation.
Furthermore, the consequence of activation of a given mol-
ecule depends on cell type, differentiation status and other
signals that cells receive. In myocytes, AKT1S1 knockdown
results in proliferation blockage at the G1 phase accompanied
by cell size increment (43). Sinceb-cells in islets are not actively
proliferating cells, we did not see any changes in cell division and
size after AKT1S1 knockdown (data not shown). We previously
demonstrated that rapamycin, an inhibitor of the mTORC1,
reduces inflammatory cytokine-triggered apoptosis of insuli-
noma NIT-1 cells (44). On the contrary, we showed in this
study that AKT1S1 knockdown and, consequently, mTORC1
pathway activation benefited islet survival; others also reported
that mTORC1 pathway activation by transgenic overexpression
of Rheb increases islet function and mass (42). Such discrepant
results of mTORC1 signaling pathway activation could be due
to: (i) different cell types used (insulinoma cells versus islet
cells); (ii) different stimulation events from the milieu
(inflammatory cytokines in (44) versus serum-free medium in
this study), (iii) different points of intervention [AKT1S1,
RPS6 and EIF4EBP1 knockdown, and AKT inhibition in this
study; mTORC1 inhibition in (44); and more upstream Rheb ac-
tivation in (42)].
In T1D, the death of islet b cells is the major cause of the
disease. In T2D, insulin resistant is the initial mechanism of
pathogenesis, but at the later stage, islets also undergo apoptosis.
We demonstrated in vitro and in vivo in animal models that a lack
of TGFBI compromised islet survival. This prompted us to
assess whether TGFBI mutation is a risk factor for both T1D
and T2D in humans.
We queried the WTCCC dataset and found that three SNPs
(rs76629798, rs139897010 and rs181018777) in the TGFBI
gene and its vicinity were found to be highly significantly asso-
ciated with T1D risks. rs139897010 and rs181018777 are rare
variants with minor allele frequency (MAF) of 0.0014, meaning
that only 0.14% of the tested population carry this mutation.
T1D isapolygenicdisease. It isexpected thatmanysuch rarepoly-
morphisms might contribute to diabetes risk for different small
subpopulations of patients.
rs76629798 is intronic, andrs139897010 is in the3′ untranslated
region 25 kb downstream of the TGFBI gene. Both these SNPs
are located in sites rich in H2K4Me1 marks, DNase I hypersensi-
tive clusters and transcription factor-binding regions, which are
features indicative of regulatory elements (enhancer/promoter)
for gene expression (45–47).
rs76629798 is intronic, andrs139897010 is in the3′ untranslated
region 25 kb downstream of the TGFBI gene. Both these SNPs
are located in sites rich in H2K4Me1 marks, DNase I hypersensi-
tive clusters and transcription factor-binding regions, which are
features indicative of regulatory elements (enhancer/promoter)
for gene expression (45–47).
In the MAGIC study, we found that rs916950, located 25 kb
upstream of the TGFBI gene, is significantly associated with
fasting glucose levels, which is a parameter with predictive
values for T2D. The SNP has MAF of 0.26, indicating a sizable
subset (26%) of the study population has this polymorphism.
This SNP is again located in a site rich in H3K4Me1, DNase
I hypersensitive clusters and transcription factor-binding
regions. Therefore, the strategic locations of these SNPs with
regard to TGFBI expression regulation raises the possibility that
such mutations could reduce TGFBI expression levels in a sub-
group of the studied populations and contribute to pathogenesis
of T2D.
In summary, using transgenic TGFBI overexpressing mouse
model in our previous study (19), and a series experiments using
TGFBI gene KO mouse model in this study, we demonstrated
that TGFBI produced by islets and their surrounding milieu
favored islet survival and function. Further investigation, based
on protein array findings, showed the involvement of AKT
and mTORC1 pathways in TGFBI signaling in islets. Genetics
studies in two human cohorts revealed that four SNPs in the
TGFBI gene and its vicinity were significantly associated with
T1D and T2D risks. These multiple indirect evidences from
animal and human studies suggest that TGFBI is likely a diabetes-
risk gene. Functional studies of the SNPs with regard to TGFBI
expression regulation and T1D and T2D incidences and severity
will be required to fully establish TGFBI as a bona fide diabetes
risk gene.
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MATERIALS AND METHODS
Generation of TGFBI KO mice
A PCR fragment amplified from the TGFBI (NM_009369.4)
cDNA sequence was used as probe to isolate genomic BAC
DNA clone 5N13 from the 129/sv mouse BAC genomic
library RPCI-22. The targeting vector was constructed by re-
combination and routine cloning methods with a 21-kb TGFBI
(NM_009369.4) genomic fragment from clone 5N13 as starting
material. A 9.67-kb (6 bp before exon 4 to the BamHI site in
intron 12) genomic fragment containing exons 4–11 was
replaced by a 1.1-kb Neo cassette from pMC1Neo-Poly A, as
illustrated in Figure 1A. The final targeting fragment was
excised from its cloning vector backbone by NotI digestion
and electroporated into R1 ES cells for G418 selection (48).
The targeted ES cell clones were injected into C57BL/6 blasto-
cysts. Chimeric male mice were mated with C57BL/6 females
to establish mutated TGFBI (NM_009369.4) allele germline
transmission.
As illustrated in Figure 1A, Southern blotting with probes cor-
responding to the 5′ and 3′ sequence (hatched rectangles) outside
the targeting region were used to screen for gene-targeted ES
cells and, eventually, confirmed gene deletion in mouse tail
DNA. The targeted and WT alleles had an 8.8- and a 12.7-kb
BglII/BglII band, respectively, using the 5′ probe; and a 7.0-kb
and a 5.3-kb NcoI/NcoI band, respectively, using the 3′ probe.
PCR was used for routine genotyping of the targeted allele(s).
The following PCR conditions were applied: 4 min at 948C, fol-
lowed by 30 cycles of 15 s at 948C, 20 s at 568C, and 20 s at 728C.
The forward primer 5′-CTGCGTGTTCGAATTCGCCAAT
GA-3′ and reverse primer 5′-GCCTGGAATGTTTCCACCC
AATGT-3′ detected a 144-bp fragment from the targeted
allele. The forward primer 5′-CACAAAGCACACAAGTGG
CAGTGA-3′ and reverse primer 5′-AACATTCCCTTGCAG
ACCCAGAGA-3′ detected a 187-bp fragment from the WT
allele.
All mice were housed under specific pathogen-free conditions
and studied according to protocols approved by the Institutional
Animal Protection Committee of the CRCHUM.
Reverse transcription–quantitative PCR
Total RNA from the islets or kidneys was extracted with TRIzol
(Invitrogen, Carlsbad, CA, USA). RNA was reverse-transcribed
into cDNA with iScript cDNA Synthesis kits (Bio-Rad Laborator-
ies, Hercules, CA, USA). iQ SYBR Green Supermix PCR kits
(Bio-Rad Laboratories) were employed for real-time PCR ampli-
fication of cDNA templates. The PCR amplification program was
as follows:958C,3 min,1cycle;958C,10 s,598C,20 s,728C,30 s,
45 cycles. Primers for TGFBI (NM_009369.4) TGFb1
(NM_011577.1), RPS6 (ribosomal protein S6, NM_009096.3)
and EIF4EBP1 (eukaryotic translation initiation factor 4E
binging protein 1, NM_007918.3) mRNA quantification are
listed in Supplementary Material, Table S1. All samples were
tested induplicate.b-ActinmRNAlevelsweremeasuredas intern-
al controls. In addition to melting curve analysis, qPCR products
were verified by agarose gel electrophoresis for expected band
sizes. The data are expressed as signal ratios of mRNA of the
tested genes/b-actin mRNA.
Enzyme-linked immunosorbent assay
Mouse TGFBI (NM_009369.4) and TGFb1 (NM_011577.1)
ELISA kits were purchased from R&D Systems (Minneapolis,
MN, USA) and eBioscience (San Diego, CA, USA), respectively.
Assays were performed according to the manufacturers’ instruc-
tions. All samples were assayed in duplicate. Sensitivity
was 8 pg/ml with TGFBI (NM_009369.4) enzyme-linked
immunosorbent assay (ELISA) and 5 pg/ml with TGFb1
(NM_011577.1) ELISA.
Islet isolation, culture, flow cytometry and
insulin-release assays
These experimental methods are detailed in our earlier publica-
tions (19). KO and WT islets were cultured in serum-free F-12K
medium containing 2% BSA and 1× MEM non-essential
amino acids before flow cytometry analysis and insulin release
assays. In some experiments, islets were cultured in the presence
of AKT inhibitor IV ((49), Calbiochem, Darmstadt, Germany) or
vehicle.
Syngeneic islet transplantation
KO and WT male mice in the second generation of 129/sv to
C57BL/6 backcrossing (10–12 weeks old) were treated i.p.
3 times with 90 mg/kg STZ every other day to chemically
induce diabetes. Two weeks after STZ injection, blood glucose
was monitored daily with an Ascensia Contour glucose meter
(Toronto, Ontario, Canada) until it was .20 mM for 2 consecu-
tive days, and these mice were then grouped as islet transplant-
ation recipients. Three hundred and fifty KO and WT islets of
the same background as that of the recipients in 20 ml phosphate-
buffered saline (PBS) were transplanted underneath the left renal
capsule of the recipients. The surgical procedure is described in
our publication (6,19). Recipient blood glucose was monitored
daily for 7 days and then once every 3 days until Day 31.
Multiple-low dose STZ-induced diabetes in KO mice
KO and WT male mice in the C57BL/6 background (10–12
weeks old) were treated i.p. with low-dose STZ (40 mg/kg,
q.d. for 5 days) to chemically induce diabetes. Blood glucose
was monitored once every 3 days from Day 6 until Day 34.
TGFb1 secretion and TGFb1-induced TGFBI
secretion by islets
Freshly isolated WT islets were starved in F-12K serum-free
medium (containing 2% BSA and 1× MEM non-essential
amino acids) for 48 h. Parts of the culture supernatants were har-
vested at 0 and 48 h for TGFb1 (NM_011577.1) measurementsby
ELISA. Exogenous mouse recombinant TGFb1 (NM_011577.1)
at 20 ng/ml (final concentration) was added at 48 h, and the islets
were cultured for another 48 h. TGFBI (NM_009369.4) levels in
supernatants were measured at different time points by ELISA.
TGFb1 and TGFBI expression in tissues adjacent to islet
transplantation sites
An incision of 5–8 mm in length was made on the renal capsule
of the left kidney of mice, and the capsule of 15–25 mm2 in
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surface size was freed from its underneath renal parenchyma
near the incision, to mimic the lacerated condition of islet trans-
plantation. Both the left (lacerated) and right (control, unmani-
pulated) kidneys were harvested 48 h later. Thin tissue slices
were pared from the left kidney in the original lacerated area
and from the corresponding area of the control right kidney.
They were homogenized and their total RNA was extracted for
the measurement of TGFb1 (NM_011577.1) and TGFBI
(NM_009369.4) mRNA levels.
Phospho-protein array analysis of 402 kinases, transcription
factors and adaptor proteins in transgenic (Tg) versus
WT islets
Islets from Tg and WT mice were isolated and cultured for 4 h.
Islets from individual mice were pooled (two mice per pool;
three pools islets from Tg mice and three pools of islets
from WT mice were used), lysed and lysate proteins were
analyzed by Full Moon BioSystem (Sunnyvale, CA, USA)
phospho-protein array which contains antibodies (Abs)
against 402 phosphorylated kinases, adaptor proteins and tran-
scription factors as well as Abs against total proteins of the




WT islets were cultured in F-12K serum-free medium in the pres-
ence of recombinant human TGFBI (NM_009369.4) (5 mg/ml)
for 4 h and then lysed. Fifty micrograms of lysate protein per
lane were loaded for 12% SDS–PAGE. Proteins in the gels
were transferred to polyvinylidene fluoride membranes after elec-
trophoresis. The membranes were hybridized with rabbit Abs
against total or phosphorylated mouse AKT (NM_001165894,
S473), AKT1S1 (NM_001253920.1, Thr246), RPS6 (NM_
009096.3, S235/S236) and EIF4EBP1 (NM_007918.3, Thr37/
Thr46). All Abs were from Cell Signaling Technology
(Danvers, MA, USA) and used at 1:1000 dilution. The hybridiza-
tion procedure was performed according to the manufacturer’s
instructions. Signals were detected with SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientific, Rockford,
IL, USA).
siRNA transfection
Mouse AKT1S1 (NM_001253920.1) and EIF4EBP1 (NM_
007918.3) siRNAs were synthesized by Integrated DNA Tech-
nologies (Coralville, IA, USA). RPS6 (NM_009096.3) siRNA
was fromThermoScientific (Pittsburgh,PA,USA).Thesequences
of siRNAs specific to AKT1S1 (NM_001253920.1), RPS6
(NM_009096.3) and EIF4EBP1 (NM_007918.3) and control
siRNA are listed in Supplementary Material, Table S2. siRNAs
were transfected into islets with X-tremeGENE transfection
reagent (Roche Diagnostics GmbH, Mannheim, Germany) at a
final concentration of 80 nM siRNA for 200 islets at 0.2 ml/well
in 48-well plates. mRNA knockdown was confirmed by RT–
qPCR 48 h after transfection.
Analysis of SNPs in the TGFBI gene for their association
with T1D and T2D
A GWAS and a meta-analysis dataset were queried for the
significance of association for all SNPs located within the
genomic region containing the TGFBI (NM_009369.4) gene
and adjacent regions 50 kb upstream and downstream of the
gene (chr5:135,315,100–135,482,840, Build 36; chr5;135,287,
201–135,454,941, Build37) with either T1D or T2D pheno-
types. The GWAS was conducted by the WTCCC, comprising
2000 T1D patients and 3000 control individuals, who are
Great Britain Caucasians (33). The meta-analysis was performed
by the MAGIC, and includes 96 496 non-diabetic individuals of
European ancestry from 52 GWAS, using fasting blood glucose
levels without or with correction for BMI as a phenotype (34).
Such a glycemic phenotype might be associated with T2D
risks. The number of tag SNPs representing independent LD
blocks within the test region was calculated using the Pairwise
Tagger Program (50,51) on the HapMap website (http://
hapmap.ncbi.nlm.nih.gov) with the r2 parameter set at 0.8 and
no minimum allele frequency. This analysis determined that
there were 42 Tag SNPs within the region using these parameter
settings. These Tag SNPs can proxy for the total of 795 SNPs
queried (231 for T2D, 737 for T1D and 173 common to both
T1D and T2D) and give a statistically conservative estimate
(using r2 of 0.8) of the number of independent tests. This estimate
of independent LD blocks was used to determine the Bonferroni-
corrected P-value at P ¼ 0.05/42 ¼ 1.19 × 1023. Only one
phenotype was examined for the WTCCC GWAS and two corre-
lated phenotypes were queried for the MAGIC meta-analysis.
Correcting for two phenotypes in the latter analysis gives a cor-
rected P-value of 5.85 × 1024, which is conservative given the
correlation between fasting glucose and BMI-corrected fasting
glucose.
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